A response to Glen Spielmans' re-analysis (PMID 33678061) criticizing the bremelanotide phase 3 trials. Defends the statistical validity and clinical meaningfulness of the RECONNECT trial outcomes, arguing that the re-analysis drew unwarranted conclusions from the same data.
Kingsberg, Sheryl A; Clayton, Anita H; Portman, David; Krop, Julie; Jordan, Robert; Lucas, Johna; Simon, James A